SwePub
Sök i LIBRIS databas

  Extended search

(WFRF:(Sboner A)) mspu:(article)
 

Search: (WFRF:(Sboner A)) mspu:(article) > Molecular sampling ...

  • Sboner, AndreaDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven CT, USA (author)

Molecular sampling of prostate cancer: a dilemma for predicting disease progression

  • Article/chapterEnglish2010

Publisher, publication year, extent ...

  • 2010-03-16
  • London, United Kingdom :BioMed Central,2010
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-56306
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-56306URI
  • https://doi.org/10.1186/1755-8794-3-8DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-41452URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:120331073URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Original Publication: Andrea Sboner, Francesca Demichelis, Stefano Calza, Yudi Pawitan, Sunita R Setlur, Yujin Hoshida, Sven Perner, Hans-Olov Adami, Katja Fall, Lorelei A Mucci, Philip W Kantoff, Meir Stampfer, Swen-Olof Andersson, Eberhard Varenhorst, Jan-Erik Johansson, Mark B Gerstein, Todd R Golub, Mark A Rubin and Ove Andren, Molecular sampling of prostate cancer: a dilemma for predicting disease progression, 2010, BMC MEDICAL GENOMICS, (3), 8. http://dx.doi.org/10.1186/1755-8794-3-8 Copyright: BioMed Central http://www.biomedcentral.com/
  • Background: Current prostate cancer prognostic models are based on pre-treatment prostate specific antigen (PSA) levels, biopsy Gleason score, and clinical staging but in practice are inadequate to accurately predict disease progression. Hence, we sought to develop a molecular panel for prostate cancer progression by reasoning that molecular profiles might further improve current clinical models. Methods: We analyzed a Swedish Watchful Waiting cohort with up to 30 years of clinical follow up using a novel method for gene expression profiling. This cDNA-mediated annealing, selection, ligation, and extension (DASL) method enabled the use of formalin-fixed paraffin-embedded transurethral resection of prostate (TURP) samples taken at the time of the initial diagnosis. We determined the expression profiles of 6100 genes for 281 men divided in two extreme groups: men who died of prostate cancer and men who survived more than 10 years without metastases (lethals and indolents, respectively). Several statistical and machine learning models using clinical and molecular features were evaluated for their ability to distinguish lethal from indolent cases. Results: Surprisingly, none of the predictive models using molecular profiles significantly improved over models using clinical variables only. Additional computational analysis confirmed that molecular heterogeneity within both the lethal and indolent classes is widespread in prostate cancer as compared to other types of tumors. Conclusions: The determination of the molecularly dominant tumor nodule may be limited by sampling at time of initial diagnosis, may not be present at time of initial diagnosis, or may occur as the disease progresses making the development of molecular biomarkers for prostate cancer progression challenging.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Demichelis, FrancescaDepartment of Pathology and LaboratoryMedicine, Weill Cornell Medical Center, New York, USA; Institute for Computational Biomedicine, Weill Cornell Medical Center, New York, USA (author)
  • Calza, StefanoKarolinska Institutet,Karolinska Institute (author)
  • Pawitan, YudiKarolinska Institutet,Karolinska Institute (author)
  • Setlur, Sunita RDepartment of Pathology, Brigham and Women's Hospital, Boston MA, USA (author)
  • Hoshida, YujinThe Broad Institute of MIT and Harvard, Cambridge MA, USA; The Dana Farber Cancer Institute, Boston MA, USA (author)
  • Perner, SvenDepartment of Pathology and LaboratoryMedicine, Weill Cornell Medical Center, New York, USA (author)
  • Adami, Hans-OlovKarolinska Institutet,Karolinska Institute (author)
  • Fall, Katja,1971-Karolinska Institutet,Karolinska Institute(Swepub:oru)kafl (author)
  • A Mucci, LoreleiHarvard University,Harvard Medical School, Boston MA, USA; Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston MA, USA; Department of Epidemiology, Harvard School of Public Health, Boston MA, USA (author)
  • Kantoff, Philip WHarvard Medical School, Boston MA, USA; The Dana Farber Cancer Institute, Boston MA, USA (author)
  • Stampfer, MeirHarvard University,Harvard Medical School, Boston MA, USA; Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Boston MA, USA; Department of Epidemiology, Harvard School of Public Health, Boston MA, USA (author)
  • Andersson, Swen-Olof,1949-Department of Urology, Örebro University Hospital, Örebro, Sweden(Swepub:oru)sfan (author)
  • Varenhorst, EberhardÖstergötlands Läns Landsting,Linköpings universitet,Urologi,Hälsouniversitetet,Urologiska kliniken i Östergötland,Department of Urology, Linköping University Hospital, Linköping, Sweden(Swepub:liu)ebeva05 (author)
  • Johansson, Jan-ErikDepartment of Urology, Örebro University Hospital, Örebro, Sweden(Swepub:oru)jkjn (author)
  • Gerstein, Mark BDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven CT, USA; Program in Computational Biology and Bioinformatics, Yale University, New Haven CT, USA; Department of Computer Science, Yale University, New Haven CT, USA (author)
  • Golub, Todd RThe Howard Hughes Medical Institute at The Broad Institute of MIT and Harvard, Cambridge MA, USA; The Broad Institute of MIT and Harvard, Cambridge MA, USA; The Dana Farber Cancer Institute, Boston MA, USA (author)
  • Rubin, Mark AMedicine, Weill Cornell Medical Center, New York, USA; The Broad Institute of MIT and Harvard, Cambridge MA, USA (author)
  • Andrén, Ove,1963-Department of Urology, Örebro University Hospital, Örebro, Sweden(Swepub:oru)oan (author)
  • Department of Molecular Biophysics and Biochemistry, Yale University, New Haven CT, USADepartment of Pathology and LaboratoryMedicine, Weill Cornell Medical Center, New York, USA; Institute for Computational Biomedicine, Weill Cornell Medical Center, New York, USA (creator_code:org_t)

Related titles

  • In:BMC Medical GenomicsLondon, United Kingdom : BioMed Central3:81755-8794

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view